




MO HEALTHNET PHARMACY PROGRAM AND BUDGET UPDATE


**MHD DRUG PA COMMITTEE SEPTEMBER 16, 2021
JOSH MOORE, PHARM D-DIRECTOR OF PHARMACY**

Eligibles by Group July 2021


Total Eligibles 1,098,103



Expenditures by Enrollment Group: July 2021
Total Spend \$152,118,207




JULY 2021 MO HEALTHNET EXPENDITURES BY SERVICE



FY22 Pharmacy Spend vs Total Medicaid Spend


Total Spend \$992,865,377.50

July 2021



Pharmacy Expenditures FY22

July 2021-Sept 2021




PHARMACY PROGRAM

TOP 4 DRUG CLASSES PER FY


HICL Description	FY 2019
PALIPERIDONE PALMITATE (Invega)	\$40,792,733
LURASIDONE HCL (Latuda)	\$37,240,789
ADALIMUMAB (Humira)	\$30,733,203
ANTIHEMOPHILIC FACTOR(FVIII)RECOMBINANT	\$25,767,689
HICL Description	FY 2020
PALIPERIDONE PALMITATE (Invega)	\$47,932,570
LURASIDONE HCL (Latuda)	\$36,752,596
ADALIMUMAB (Humira)	\$35,512,453
METHLYPHENIDATE HCL (ADHD)	\$28,435,400
HICL Description	FY 2021
PALIPERIDONE PALMITATE (Invega)	\$50,536,989
ADALIMUMAB (Humira)	\$47,544,776
LURASIDONE HCL (Latuda)	\$40,495,985
METHYLPHENIDATE HCL (ADHD)	\$30,831,744
HICL Description	FYTD 2022
PALIPERIDONE PALMITATE (Invega)	\$13,354,087
ADALIMUMAB (Humira)	\$14,496,703
LURASIDONE HCL (Latuda)	\$10,614,409
ELEXACAFTOR/TEZACAFTOR/IVACAFTOR(Trikafta)	\$8,385,842

Pharmacy Expenditures/Eligibles Per FY

Table 23




HEP C FY 2018 -FYTD 2022



 Total Spend	\$48,463,198	\$38,401,858	\$37,760,135	\$31,216,308	\$6,135,357
 Total Claims	3202	2568	2125	1787	395

SYNAGIS EXPENDITURES FY2019-FYTD2022



FY2019-FYTD 2022 Rare Disease Expenditures

